Prepared by Dr. David Miller, CFA, Director of US Markets | Reviewed by Anna Kowalski, Lead Editor | Report ID: IGEMINI-0C66B652-20260531 | Data as of 2026-05-31
Executive Summary: 403 b plan operates in the Healthcare industry with a market cap of $13.8B. The stock trades at 81.32x earnings and exhibits 28.1% top-line growth. Our derived fair value is $3044.05.
Rating: Buy | Target Price: $3044.05 | Next Earnings: Jun 07
Download Full PDF Report
Price action carved a Inverse Head and Shoulders, confirmed by a 1.19x volume spike on May 24, 2026. The support at $2911.7 was tested.
MACD printed a Neutral as the 50-day SMA turned positive 16 days ago.
On-chain money flow shows 17%% increase in smart money index, reinforcing the technical setup.
EPS of $32.55 reveals high earnings quality. DuPont analysis highlights operating leverage as the key ROE driver.
Free cash flow conversion remains robust at 89%, supporting the 4.96% dividend and buybacks.
Relative to Healthcare peers, 403 b plan sits at the 84th percentile in valuation, offering a potential value opportunity.
Short float at 6.9% is below the sector average, reducing squeeze risk. Institutional ownership is 64%.
Options skew is toward put at the 2858.76 strike, positioning for a directional move.
Beta of 0.89 suggests 403 b plan is {beta_desc} volatile than the market, influencing hedging strategies.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $2647 | $2514.65 |
| Market Cap | $13.8B | $15.18B |
| P/E Ratio | 81.32x | 69.1x |
| EPS (TTM) | $32.55 | $29.3 |
| Dividend Yield | 4.96% | 3.5% |
| Revenue Growth | 28.1% | 16.9% |
| Target Price | $3044.05 | - |
| Beta | 0.89 | 1.00 |